This site is for US residents only. For Non-US Residents

About Sucraid®

What is Sucraid®?

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement that facilitates breakdown of sucrose (sugar) into simpler forms for absorption from the intestine into the blood. It can help relieve the gastrointestinal symptoms associated with Genetic Sucrase-Isomaltase Deficiency/Congenital Sucrase-Isomaltase Deficiency, and as a result, patients can maintain a more normal diet with respect to sucrose-containing foods.

  • gsid Sucraid product photoSucraid® is available in 118 mL translucent plastic bottles, packaged two bottles per box.
  • Each mL of solution contains 8,500 International Units (I.U.) of sacrosidase.
  • A 1 mL measuring scoop is provided with each bottle.

Genetic Sucrase-Isomaltase Deficiency

In 1960, Weijers and colleagues discovered Congenital Sucrase-Isomaltase Deficiency, an autosomal recessive disease of the small intestine that is also known as Genetic Sucrase-Isomaltase Deficiency. The disease was originally characterized by undetectable sucrase activity, a decrease of maltase activity to nearly one third of the normal level and a varying degree of isomaltase activity.

Sucraid® does not break down starch (e.g., potato, bread, pasta) and some Genetic Sucrase-Isomaltase Deficiency patients also have an inability to absorb starch from their diet. It is advisable for patients to restrict the amount of dietary starch for two weeks when starting Sucraid® and gradually reintroduce starch. Keeping a dietary diary for the first few weeks of therapy is also recommended.

How Does Sucraid® Work?

Csid gsid sucrase microvilli

Sucraid® catalyzes the hydrolysis of sucrose to glucose and fructose, facilitating the breakdown and absorption of sucrose in the small intestine.

Sucraid® is a sucrase enzyme replacement therapy that catalyzes the hydrolysis of sucrose into glucose and fructose, thereby facilitating absorption from the small intestine into the bloodstream. Sucraid® has been shown to be an effective treatment for patients with Genetic Sucrase-Isomaltase Deficiency. The sacrosidase in Sucraid® is potent and robust; on a per milliliter basis, Sucraid® is approximately 100-fold more potent than endogenous sucrase.1 It has been shown to be stable when stored at 4°C.2

Although Sucraid® provides replacement therapy for deficient sucrase, it does not provide specific replacement therapy for deficient isomaltase.3 Therefore, restricting starch in the diet may still be necessary to reduce symptoms as much as possible. The need for dietary starch restriction for patients using Sucraid® should be evaluated in each patient.

References

  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gatroenterol Nutr. 1999; 28:137-142.
  2. Treem WR, Ahsan N, Sullivan B, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gatroenterology. 1993; 105:1061-1068.
  3. Sucraid® (sacrosidase) Oral Solution Full Prescribing Information.
QOL Medical, LLC